Modifying Factors in Striated Muscle Laminopathies (LMNAModifier)

Identification of Genetic Modifying Factors in Striated Muscle Laminopathies

Mutations in the LMNA gene, which codes for lamins A and C, proteins of the nuclear lamina, are responsible for a wide spectrum of pathologies, including a group specifically affecting striated skeletal and cardiac muscles, with cardiac involvement being life-threatening. At the skeletal muscle level, a wide phenotypic spectrum has been described, ranging from severe forms of congenital muscular dystrophy to less severe forms of limb-girdle muscular dystrophy. The great clinical variability of striated muscle laminopathies, both inter- and intra-familial, can be observed in the age of onset, severity of signs and progression of muscle and heart involvement. To date, more than 400 LMNA mutations have been associated with striated muscle laminopathies (www.umd.be/LMNA/), highlighting strong clinical and genetic heterogeneity. A few recurrent mutations linked to a difference in severity have been identified. However, these genotype-phenotype relationships and the rare cases of digenism reported do not explain all the clinical variability of laminopathies. Therefore, there are probably other factors of severity than the causative mutation, called "modifier genes".

Identification of such modifier genes has been initiated by studying a large family with significant clinical variability in the age of onset of muscle signs. A segregation analysis within this family identified 2 potential modifier loci. High-throughput sequencing restricted to these 2 regions according to phenotypic subgroups did not led to meaningful results so far. In addition, an international retrospective study of the natural history of early muscle laminopathies has allowed the investigators to highlight a strong inter-family clinical variability in patients carrying recurrent mutations. The investigators thus have strong preliminary data that could allow them to identify modifying genetic factors in a cohort of patients carrying a mutation in the LMNA gene.

In order to identify these factors that modulate the clinical severity of laminopathies, the investigators wish to collect biological material (muscle and/or skin biopsies) from patients carrying a mutation in the LMNA gene. The study of this biological material using multi OMICs technics will allow the investigators to identify and functionally validate the action of these modifying genes.

OMIICs is a set of techniques for characterising biological molecules using high-throughput approaches such as DNA sequencing, RNA sequencing and/or chromatin conformation (ATACseq...), proteins.

Study Overview

• Status: Recruiting
• Conditions: Laminopathies; Emery Dreifuss Muscular Dystrophy 2; LMNA-Related Congenital Muscular Dystrophy; Dilated Cardiomyopathy-1A
• Intervention / Treatment: Procedure: Skin Biopsy; Procedure: Muscle biopsy

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Gisele Bonne, Phd; Phone Number: +33142165724; Email: g.bonne@institut-myologie.org
• Study Contact Backup: Name: Rabah Ben Yaou, MD; Phone Number: +33142165735; Email: r.benyaou@institut-myologie.org

Study Locations

• France
  • Auvergne-Rhône-Alpes
    • Bron, Auvergne-Rhône-Alpes, France, 69677
      • Recruiting
      • Centre de référence maladies neuromusculaires, Hôpital Femme Mère Enfant, CHU Lyon
      • Contact: Françoise Bouhour, MD; Email: françoise.bouhour@chu-lyon.fr
      • Contact: Véronique Manel, MD; Email: veronique.manel@chu-lyon.fr
  • France
    • Paris, France, France, 75013
      • Recruiting
      • Centre de référence maladies neuromusculaires, Institut de myologie, Hôpital Pitié-Salpêtrière
      • Contact: Tanya Stojkovic, MD; Email: tanya.stojkovic@aphp.fr
      • Contact: Anthony Behin, MD; Phone Number: +3342163774; Email: anthony.behin@aphp.fr
  • Hérault
    • Montpellier, Hérault, France, 34295
      • Not yet recruiting
      • Service de Neuropédiatrie, Centre de Référence Maladies Neuromusculaires, CHU de Montpellier
      • Contact: François Rivier, MD; Phone Number: +33467330182; Email: f-rivier@chu-montpellier.fr
  • Ille-et-Vilaine
    • Rennes, Ille-et-Vilaine, France, 35000
      • Not yet recruiting
      • Service de Génétique médicale, CHU Rennes
      • Contact: Melanie Fradin, MD; Phone Number: +33299266744; Email: melanie.fradin@chu-rennes.fr
  • Loire-Atlantique
    • Nantes, Loire-Atlantique, France, 44093
      • Not yet recruiting
      • Laboratoire d'Explorations Fonctionnelles - Centre de Référence Maladies Neuromusculaires Rares, CHU Nantes
      • Contact: Yann Pereon, MD; Phone Number: +33240083617; Email: Yann.Pereon@univ-nantes.fr
      • Contact: Sandra Mercier, MD; Phone Number: +33240083245; Email: sandra.mercier@chu-nantes.fr
  • Normandy
    • Rouen, Normandy, France, 76031
      • Recruiting
      • Service de cardiologie & Service de Neurophysiologie - CHU de Rouen
      • Contact: Frédéric Anselme, MD; Phone Number: +33232888111; Email: Frederic.Anselme@chu-rouen.fr
      • Contact: Lucie Guyant-Marechal, MD; Phone Number: +33232888037; Email: lucie.guyant@chu-rouen.fr
  • Paris
    • Paris, Paris, France, 75013
      • Recruiting
      • Centre de référence pour les maladies cardiaques héréditaires
      • Contact: Philippe Charron, MD; Phone Number: +33142162892; Email: philippe.charron@aphp.fr
  • Île-de-France Region
    • Garches, Île-de-France Region, France, 92380
      • Not yet recruiting
      • Service de Neurologie, Réanimation Pédiatriques, Hôpital Raymond Poincaré, Hôpitaux Universitaires, Paris-Ile-de-France-Ouest
      • Contact: Susana Quijano-Roy, MD; Phone Number: +33147417890; Email: susana.quijano-roy@aphp.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patient with an LMNA mutation that has led to the diagnosis of laminopathy affecting striated muscle
• Presenting the symptoms of the disease, whether they are index cases or related to this index case (muscle weakness, tendon retractions with or without respiratory or cardiac involvement)
• Have no contraindication to muscle or skin biopsy, i.e., 1) presence of a history of allergy to latex, antiseptics, local anesthetics and adhesive dressings, 2) Current oral or parenteral anticoagulant therapy (anti-vitamin K, heparins, anti-platelet agents, anti-factor X, anti-thrombin), 3) History of inherited (haemophilias, platelet diseases) or acquired (vitamin K deficiency, liver failure) coagulation disorders.
• Patients (adult participant) or both holders of parental authority (minor participant) must sign a free and informed consent. If a minor has only 1 legal representative, the latter must attest to this on the consent form.
• Patients affiliated to the general French social security system, to the French Universal Medical Coverage (CMU) or to any French equivalent scheme.

Exclusion Criteria:

• Pregnant or breastfeeding women
• Adult subject to legal protection measures (safeguard of justice, curatorship and guardianship).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Other: Collection of biological material; Patients carrying LMNA mutation with no contrindication for skin and/or muscle biopsy: from large families with striking intrafamilial phenotypic variability (3 families identified).; patients carrying p.Arg453Trp or p.Glu358Lys LMNA gene mutations

Procedure: Skin Biopsy; The skin biopsy is performed in the consultation outclinic room. A local anaesthetic (anaesthetic patch to be applied to the skin) is required for this procedure. The skin biopsy is usually performed on the front of the forearm (but can be performed on the arm, thigh or leg). After disinfection, a fragment of 3 to 4 mm in diameter is removed with a biopsy-punch (single-use device). If necessary, a suture can be placed. Otherwise, the wound is covered with Steristrip and a sterile dressing. The skin sample, intended for a fibroblast culture, will be placed in a flask to be kept at room temperature. It will be labelled with specific labels and sent to the local biological resource centre.; Procedure: Muscle biopsy; The muscle biopsy is performed in a sterile room. A local anaesthetic is required for this procedure. After selecting the muscle from which the sample will be taken (usually from the deltoid muscle at the shoulder stump), placing a sterile field and disinfecting, a small incision is made in the skin until the selected muscle is exposed. A bundle of muscle fibres of approximately 1 cm x 0.5 cm is removed. The skin is then sutured and covered with a sterile dressing. The procedure takes about 30 minutes (including patient set-up). The muscle sample will be divided into 2 fragments, one for myoblast culture, the other for frozen tissue. The 2 vials will be labelled with specific labels and then sent to the local biological resource centre

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Skeletal muscle severity outcome	Will be a composite scale combining maximal motor acquisitions (sitting, walking, running) and what remains as motor skills with disease course (still running, only walking, only sitting, inability to sit)). In details: The maximal motor acquisitions (M2A) : no motor acquisitions = 0, only rolling = 1, only sitting = 2, only walking = 3, running = 4.; The remaining motor skills (RMS) with disease course: still running = 3, only walking = 2, only sitting = 1, inability to sit = 0. The composite scale for a given patient will be M2A + RMS.	5 years
Cardiac muscle severity outcome	Will be a composite scale according to left ventricle ejection fraction (normal>55%, moderate <55% and >45%, severe<45%) and the presence or absence of conduction defects and arrhythmias.	5 years
Protective structural variant outcome	Structural gene variants identified on patient biological materials by Whole Genome Sequencing (WGS), associated with the mild disease severity.	5 years
Protective differential gene expression outcome	differential gene expression identified on patient biological materials by RNA sequencing (RNA-seq) associated with the mild disease severity.	5 years
Protective 3D chromatin conformation outcome	3D conformation of chromatin identified on patient biological materials by Chromatin Immuno-Precipitaiton Sequencing (CHIP Seq) associated with the mild disease severity.	5 years
Aggravating structural variant outcome	Structural gene variants identified on patient biological materials by Whole Genome Sequencing (WGS), associated with the worse disease severity.	5 years
Aggravating differential gene expression outcome	Differential gene expression identified on patient biological materials by RNA sequencing (RNA-seq) associated with the worse disease severity.	5 years
Aggravating 3D chromatin conformation outcome outcome	3D conformation of chromatin identified on patient biological materials by Chromatin Immuno-Precipitaiton Sequencing (CHIP Seq) associated with the worse disease severity.	5 years

Collaborators and Investigators

• Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Publications and helpful links

General Publications

• Granger B, Gueneau L, Drouin-Garraud V, Pedergnana V, Gagnon F, Ben Yaou R, Tezenas du Montcel S, Bonne G. Modifier locus of the skeletal muscle involvement in Emery-Dreifuss muscular dystrophy. Hum Genet. 2011 Feb;129(2):149-59. doi: 10.1007/s00439-010-0909-1. Epub 2010 Nov 10.
• Ben Yaou R, Yun P, Dabaj I, Norato G, Donkervoort S, Xiong H, Nascimento A, Maggi L, Sarkozy A, Monges S, Bertoli M, Komaki H, Mayer M, Mercuri E, Zanoteli E, Castiglioni C, Marini-Bettolo C, D'Amico A, Deconinck N, Desguerre I, Erazo-Torricelli R, Gurgel-Giannetti J, Ishiyama A, Kleinsteuber KS, Lagrue E, Laugel V, Mercier S, Messina S, Politano L, Ryan MM, Sabouraud P, Schara U, Siciliano G, Vercelli L, Voit T, Yoon G, Alvarez R, Muntoni F, Pierson TM, Gomez-Andres D, Reghan Foley A, Quijano-Roy S, Bonnemann CG, Bonne G. International retrospective natural history study of LMNA-related congenital muscular dystrophy. Brain Commun. 2021 Apr 11;3(3):fcab075. doi: 10.1093/braincomms/fcab075. eCollection 2021 Jul.

Helpful Links

• UMD LMNA mutation database

Study record dates

Study Major Dates

• Study Start (Actual): September 8, 2022
• Primary Completion (Estimated): September 30, 2027
• Study Completion (Estimated): December 30, 2027

Study Registration Dates

• First Submitted: March 30, 2022
• First Submitted That Met QC Criteria: May 23, 2022
• First Posted (Actual): May 27, 2022

Study Record Updates

• Last Update Posted (Actual): March 4, 2026
• Last Update Submitted That Met QC Criteria: March 3, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: A-type lamins; LMNA; muscular dystrophy; modifier factor
• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Nervous System Diseases; Cardiovascular Diseases; Muscular Diseases; Heart Diseases; Neuromuscular Diseases; Genetic Diseases, Inborn; Cardiomyopathies; Muscular Disorders, Atrophic; Cardiomegaly; Muscular Dystrophy, Emery-Dreifuss; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Autosomal Emery-Dreifuss Muscular Dystrophy; Laminopathies; Muscular Dystrophies; Cardiomyopathy, Dilated; Muscular Dystrophy, Congenital, Lmna-Related
• Other Study ID Numbers: C20-45

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No